Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 8 for:    cvncov | Covid19
Previous Study | Return to List | Next Study

A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04652102
Recruitment Status : Active, not recruiting
First Posted : December 3, 2020
Last Update Posted : July 22, 2021
Sponsor:
Information provided by (Responsible Party):
CureVac AG

Brief Summary:
This study aims to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants.

Condition or disease Intervention/treatment Phase
Covid19 SARS-CoV-2 Biological: CVnCoV Biological: Placebo Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39693 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
Actual Study Start Date : December 14, 2020
Actual Primary Completion Date : April 16, 2021
Estimated Study Completion Date : May 15, 2022

Arm Intervention/treatment
Experimental: Phase 2b: CVnCoV vaccine
Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
Biological: CVnCoV
Intramuscular (IM) injection.
Other Name: CV07050101

Placebo Comparator: Phase 2b: Placebo
Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
Biological: Placebo
Intramuscular (IM) injection.

Experimental: Phase 3: CVnCoV vaccine
Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
Biological: CVnCoV
Intramuscular (IM) injection.
Other Name: CV07050101

Placebo Comparator: Phase 3: Placebo
Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
Biological: Placebo
Intramuscular (IM) injection.




Primary Outcome Measures :
  1. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity [ Time Frame: Day 1 to Day 393 ]
  2. Number of participants who experience one or more medically-attended adverse events (AEs) [ Time Frame: Day 29 to Day 211 ]
  3. Intensity grading of medically-attended adverse events (AEs) per FDA toxicity grading scale [ Time Frame: Day 29 to Day 211 ]
  4. Number of participants who experience one or more treatment-related medically-attended adverse events (AEs) [ Time Frame: Day 29 to Day 211 ]
  5. Number of participants who experience one or more serious adverse events (SAEs) [ Time Frame: Day 29 to Day 393 ]
  6. Intensity grading of serious adverse events (SAEs) per FDA toxicity grading scale [ Time Frame: Day 29 to Day 393 ]
  7. Number of participants who experience one or more treatment-related serious adverse events (SAEs) [ Time Frame: Day 29 to Day 393 ]
  8. Number of participants who experience one or more adverse events of special interest (AESI) [ Time Frame: Day 29 to Day 393 ]
  9. Intensity grading of adverse events of special interest (AESI) per FDA toxicity grading scale [ Time Frame: Day 29 to Day 393 ]
  10. Number of participants who experience one or more treatment-related adverse events of special interest (AESI) [ Time Frame: Day 29 to Day 393 ]
  11. Number of participants who experience a fatal serious adverse event (SAE) [ Time Frame: Day 29 to Day 393 ]

Secondary Outcome Measures :
  1. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} moderate to severe case of COVID-19 [ Time Frame: Day 1 to Day 393 ]
  2. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} severe case of COVID-19 [ Time Frame: Day 1 to Day 393 ]
  3. Number of participants who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity due to infection with "wild type" and "UK" SARS-CoV-2 strains [ Time Frame: Day 1 to Day 393 ]
    Measured in SARS-CoV-2 naïve participants.

  4. Number of participants with seroconversion to the nucleocapsid (N) protein of SARS-CoV-2 ≥ 15 days after the second study vaccination [ Time Frame: Days 1, 43, 211 and 393 ]
    Seroconversion is defined as detectable SARS-CoV-2 N protein antibodies in the serum of asymptomatic seronegative participants who tested seronegative on Day 1 and on Day 43.

  5. Number of participants aged ≥ 61 who experience a first episode of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity [ Time Frame: Day 1 to Day 393 ]
  6. Number of participants who experience a virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} SARS-CoV-2 infection, with or without symptoms [ Time Frame: Day 1 to Day 393 ]
  7. Burden of disease (BoD) based on first episodes of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} cases of COVID-19 [ Time Frame: Day 1 to Day 393 ]
  8. Number of participants who experience a virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} case of COVID-19 of any severity with symptom onset at any time after the first study vaccination [ Time Frame: Post vaccination on Day 1 up to Day 393 ]
  9. Number of participants with serum antibodies to SARS-CoV-2 spike (S) protein [ Time Frame: Days 1, 29, 43, 57, 120, 211 and 393 ]
    S protein will be measured by enzyme-linked immunosorbent assay (ELISA).

  10. Number of participants who experience seroconversion to SARS-CoV-2 spike (S) protein [ Time Frame: Days 1, 29, 43, 57, 120, 211 and 393 ]
    S protein will be measured by enzyme-linked immunosorbent assay (ELISA). Seroconversion is defined as detectable SARS-CoV-2 S protein antibodies in the serum of participants who tested seronegative on Day 1.

  11. Number of participants with serum vital neutralizing antibodies to SARS-CoV-2 virus [ Time Frame: Days 1, 29, 43, 57, 120, 211 and 393 ]
    Serum vital neutralizing antibodies to SARS-CoV-2 virus will be measured by a viral neutralizing antibody assay.

  12. Number of participants who experience seroconversion to SARS-CoV-2 virus [ Time Frame: Days 1, 29, 43, 57, 120, 211 and 393 ]
    Seroconversion to SARS-CoV-2 virus will be measured by a viral neutralizing antibody assay. Seroconversion is defined as detectable SARS-CoV-2 viral neutralizing antibodies in the serum of participants who tested seronegative on Day 1.

  13. Phase 2b participants only: Number of participants who experience one or more solicited local adverse events (AEs) [ Time Frame: 7 days after vaccination ]
  14. Phase 2b participants only: Intensity grading of solicited local adverse events (AEs) per FDA toxicity grading scale [ Time Frame: 7 days after vaccination ]
  15. Phase 2b participants only: Duration of solicited local adverse events (AEs) [ Time Frame: 7 days after vaccination ]
  16. Phase 2b participants only: Number of participants who experience one or more solicited systemic adverse events (AE) [ Time Frame: 7 days after vaccination ]
  17. Phase 2b participants only: Intensity grading of solicited systemic adverse events (AEs) [ Time Frame: 7 days after vaccination ]
  18. Phase 2b participants only: Duration of solicited systemic adverse events (AEs) [ Time Frame: 7 days after vaccination ]
  19. Phase 2b participants only: Number of participants who experience one or more unsolicited adverse events (AEs) [ Time Frame: 28 days after vaccination ]
  20. Phase 2b participants only: Intensity grading of unsolicited adverse events (AEs) [ Time Frame: 28 days after vaccination ]
  21. Phase 2b participants only: Number of participants who experience one or more treatment-related unsolicited adverse events (AEs) [ Time Frame: 28 days after vaccination ]
  22. Number of participants who experience one or more adverse events (AEs) leading to vaccine withdrawal or trial discontinuation [ Time Frame: Day 29 to Day 393 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female participants 18 years of age or older.
  • Be willing and able to provide written informed consent prior to initiation of any trial procedures.
  • Expected compliance with protocol procedures and availability for clinical follow-up through the last planned visit.
  • Females of non-childbearing potential defined as follows: surgically sterile (history of bilateral tubal ligation/occlusion, bilateral oophorectomy or hysterectomy) or postmenopausal {defined as amenorrhea for ≥12 consecutive months prior to screening (Day 1) without an alternative medical cause}. A follicle-stimulating hormone (FSH) level may be measured at the discretion of the Investigator to confirm postmenopausal status.
  • Females of childbearing potential: negative pregnancy test (human chorionic gonadotropin [hCG]) within 24 hours prior to each trial vaccination on Day 1 and Day 29.
  • Females of childbearing potential must use highly effective methods of birth control from 2 weeks before the first administration of the trial vaccine until 3 months following the last administration. The following methods of birth control are considered highly effective when used consistently and correctly:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal);
    • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable);
    • Intrauterine devices (IUDs);
    • Intrauterine hormone-releasing systems (IUSs);
    • Bilateral tubal ligation;
    • Vasectomized or infertile partner;
    • Sexual abstinence {periodic abstinence (e.g., calendar, ovulation, symptothermal and post-ovulation Methods) and withdrawal are not acceptable}.

Exclusion Criteria:

  • History of virologically-confirmed COVID-19 illness.
  • For females: pregnancy or lactation.
  • Use of any investigational or non-registered product (vaccine or drug) within 28 days preceding the administration of trial vaccine or planned use during the trial.
  • Receipt of any licensed vaccines within 28 days (for live vaccines) or 14 days (for inactivated or any other vaccines) prior to administration of the first trial vaccine.
  • Prior administration of any investigational SARS-CoV-2 vaccine or another coronavirus (SARS-CoV, Middle East Respiratory Syndrome-CoV) vaccine or planned used during the trial.
  • Any treatment with immunosuppressants or other immune-modifying drugs (including but not limited to anabolic steroids, corticosteroids, biologicals and methotrexate) for > 14 days total within 6 months preceding the administration of trial vaccine or planned use during the trial. For corticosteroid use, this means prednisone or equivalent, 0.5 mg/kg/day for 14 days or more. The use of inhaled, topical, or localized injections of corticosteroids (e.g., for joint pain/inflammation) is permitted.
  • Any medically diagnosed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination including known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); current diagnosis of or treatment for cancer including leukemia, lymphoma, Hodgkin disease, multiple myeloma or generalized malignancy; chronic renal failure or nephrotic syndrome; and receipt of an organ or bone marrow transplant.
  • History of angioedema (hereditary or idiopathic) or history of any anaphylactic reaction.
  • History of potential immune-mediated disease (pIMD).
  • History of allergy to any component of CVnCoV.
  • Administration of immunoglobulins or any blood products within 3 months prior to the administration of trial vaccine or planned receipt during the trial.
  • Participants with a significant acute or chronic medical or psychiatric illness that, in the opinion of the Investigator, precludes trial participation (e.g., may increase the risk of trial participation, render the participant unable to meet the requirements of the trial, or may interfere with the participant's trial evaluations). These include severe and/or uncontrolled cardiovascular disease, gastrointestinal disease, liver disease, renal disease, respiratory disease, endocrine disorder, and neurological and psychiatric illnesses. However, those with controlled and stable cases can be included in the trial.
  • Participants with impaired coagulation or any bleeding disorder in whom an intramuscular injection or a blood draw is contraindicated.
  • Foreseeable non-compliance with the trial procedure as judged by the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04652102


Locations
Show Show 53 study locations
Sponsors and Collaborators
CureVac AG
Layout table for additonal information
Responsible Party: CureVac AG
ClinicalTrials.gov Identifier: NCT04652102    
Other Study ID Numbers: CV-NCOV-004
2020-003998-22 ( EudraCT Number )
First Posted: December 3, 2020    Key Record Dates
Last Update Posted: July 22, 2021
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CureVac AG:
Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases